Published in Histochemistry on January 01, 1986
Binding of swine IgM immunoglobulins to peripheral nerve myelin sheaths in electron microscopic immunocytochemistry. Acta Neuropathol (1988) 0.79
Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet (1997) 6.99
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst (1999) 2.90
Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut (2009) 2.75
bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol (1997) 2.66
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol (2001) 2.42
p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol (2001) 2.19
Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. J Pathol (1993) 2.12
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology (1999) 1.74
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Outcome of special types of luminal breast cancer. Ann Oncol (2011) 1.67
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med (2001) 1.57
Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer (2003) 1.55
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med (1998) 1.53
Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol (1996) 1.52
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer (1994) 1.51
Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol (2011) 1.50
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol (2010) 1.47
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol (2014) 1.45
The problem of the accuracy of intraoperative examination of axillary sentinel nodes in breast cancer. Ann Surg Oncol (2001) 1.45
Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat (2009) 1.41
Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res (1995) 1.39
Immunoreactivity for latent membrane protein 1 of Epstein-Barr virus in nevi and melanomas is not related to the viral infection. Virchows Arch (2000) 1.39
Restoration of posterior aspect of rhabdosphincter shortens continence time after radical retropubic prostatectomy. J Urol (2006) 1.39
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst (1994) 1.35
p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol (1995) 1.32
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol (2006) 1.29
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol (2014) 1.24
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol (2008) 1.23
Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg (1999) 1.22
Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature. Mod Pathol (2001) 1.22
bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol (1995) 1.21
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol (2012) 1.19
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol (2007) 1.17
Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene (2009) 1.16
A simplified procedure for the preparation of antibodies to serum fibronectin. J Immunol Methods (1980) 1.13
Resection of pulmonary blebs and pleurodesis for spontaneous pneumothorax. Chest (1993) 1.12
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat (2011) 1.12
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer (1996) 1.11
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol (1999) 1.10
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol (2004) 1.10
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer (1997) 1.10
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol (1999) 1.10
Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. AIDS (1993) 1.09
Radioguided occult lesion localisation (ROLL) and surgical biopsy in breast cancer. Technical aspects. Q J Nucl Med (2002) 1.08
Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer (2001) 1.07
Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology (2000) 1.07
The clinical significance of p53 aberrations in human tumours. Virchows Arch (1995) 1.06
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol (2007) 1.06
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol (2006) 1.06
Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol (1983) 1.06
Soluble CD14(1-152) confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay. J Immunol (1998) 1.06
Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer (2007) 1.04
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol (2012) 1.04
A study of immunoglobulin classes present on the membrane and in the cytoplasm of human tonsil plasma cells. Eur J Immunol (1976) 1.04
Gene expression analysis of early and advanced gastric cancers. Oncogene (2007) 1.03
Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies. Lab Invest (2001) 1.03
The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch (1994) 1.03
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer (2008) 1.02
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol (2012) 1.01
Comparative study of membrane and intracytoplasmic immunoglobulin classes in human lymphoid cells. Ann N Y Acad Sci (1975) 1.01
IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes. J Immunol (1995) 1.01
Lymphocyte membrane receptors in human lymphoid leukemias. Eur J Immunol (1975) 1.00
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol (2011) 1.00
p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol (1993) 0.98
Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol (2011) 0.98
Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol (1995) 0.98
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol (2000) 0.98
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch A Pathol Anat Histopathol (1991) 0.98
Choroid plexus tumors. An immunocytochemical study with particular reference to the coexpression of intermediate filament proteins. Am J Pathol (1987) 0.97
Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept. Eur J Nucl Med Mol Imaging (2006) 0.97
p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol (1993) 0.97